Small cap opportunities with “strategic assets”
About this video
Key points:
Rotation into “strategic assets” in small caps, especially healthcare and critical minerals
EV Health (ASX:EVE) seen as leveraged to potential TGA approval-driven revenue growth
European Lithium (ASX:EUR) positioned as a strategic European critical metals play
Director and strategic investor buying viewed as confidence indicators in these small caps
John Athanasiou from Red Leaf Securities views the current small cap environment as defined by a shift towards “strategic assets”, particularly healthcare and critical minerals, as investors respond to ongoing geopolitical tensions such as the US–Iran conflict. He points to selective opportunities rather than broad-based buying, arguing that investors should treat these exposures as smaller, high-conviction positions within portfolios.
Athanasiou highlights EV Health (ASX:EVE), a producer of nutrition, health and wellness products with a focus on erectile dysfunction, as one such opportunity. He notes the share price move from $0.02 to $0.03 and points to continued on-market accumulation by a major strategic investor with Therapeutic Goods Administration approval expertise. In his view, successful TGA approval represents a key potential revenue inflection point, though he stresses the stock is thinly traded and more suited to a minor, speculative allocation.
In critical minerals, Athanasiou favours European Lithium (ASX:EUR), citing its European location as strategically important given the region’s push for secure critical metal supply. He notes strong year-to-date performance and ongoing on-market director buying, which he interprets as a sign of confidence and further upside potential, even after a significant run.